Epidemiological and clinical characteristics in patients with SARS-CoV-2 antibody negative probable COVID-19 in Wuhan

Running head SARS-CoV-2 AbN COVID-19 patients need attentions

Limin Duan MD†, Shuai Zhang MD†, Mengfei Guo PhD †, E Zhou MS†, Jinshuo Fan MD, Xuan Wang MD, Ling Wang MS2, Feng Wu PhD1, Yang Jin MD*

1 Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei, 430022, China

2 Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

†These authors contributed equally to this work

*Correspondence to: Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, China.

Yang Jin, Tel.: +86-13554361146, E-mail: whuhjy@126.om.

Acknowledgments

We thank all the patients who consented to donate their data for analysis and the medical staff members who are on the front line of caring for patients.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

**Background** Patients with suspected COVID-19 might be admitted to hospital. We aimed to describe the characteristic of SARS-CoV-2 antibody negative probable COVID-19 patients and give some suggestions to manage suspected COVID-19 patients.

**Methods** We analyzed 616 confirmed COVID-19 patients and 35 SARS-CoV-2 antibody negative probable COVID-19 patients who were admitted in Wuhan Union Hospital from February 13, 2020 to February 16, 2020. Telephone interviews were conducted and medical records were reviewed for epidemiological, clinical, laboratory and radiographic data.

**Results** Of the 35 SARS-CoV-2 antibody negative probable COVID-19 patients, all of them had tested at least 3 times of nucleic acid, 3 were believed to be non-SARS-CoV-2 infection. Compared with confirmed patients, antibody negative probable patients were younger (P=0.017), exhibited similar symptoms and chest CT images, had higher lymphocyte count (P=0.004) and albumin level (P<0.001), showed lower lactate dehydrogenase level (P=0.011) and erythrocyte sedimentation rate (P<0.001). During hospitalization, all the 35 patients had contacted with confirmed COVID-19 patients, but all used general face mask for protection and maintained a social distance of more than one meter from each other. All the isolation wards were kept ventilation and disinfected once a day. After discharged from hospital, all of them had negative nucleic acid tests and no one developed symptoms again.

**Conclusions** The conditions of patients with AbN probable COVID-19 were less critical than those of patients with confirmed COVID-19. Room ventilation and daily disinfection, wearing face masks,
and maintaining social distance might be helpful to prevent patients from hospital acquired COVID-19 infection.

**Keywords** SARS-CoV-2, antibody, suspected COVID-19 patients, hospital management

**Introduction**

Since December 2019, an ongoing outbreak of Coronavirus disease 2019 (COVID-19) has struck Wuhan, China and then spread all around the world.\(^1\)\(^-\)\(^3\) As of May 25, 2020, there have been a total of 5304772 laboratory-confirmed cases of COVID-19 reported to WHO globally, with 342029 world-wide.\(^4\) Currently, the early diagnosis of COVID-19 relies on specialized nucleic acid-based reverse transcription polymerase chain reaction (RT-PCR) testing. However, it has been reported that the positive rate of RT-PCR detection of nasopharyngeal swab and oropharyngeal swab was quite low.\(^5\) Chen et al. have listed several reasons why patients with suspected and confirmed COVID-19 should be hospitalized to hospital.\(^6\) Meanwhile, World Health Organization (WHO) also suggested to screen and isolate all patients with suspected COVID-19 at the first point of contact with the health care system.\(^7\) Therefore, during the pandemic of COVID-19, many patients with suspected COVID-19 might be admitted to hospital, even some of them might be conventional infection.

Many studies have reported the epidemiology and clinical characteristics of patients with confirmed COVID-19.\(^1\)\(^-\)\(^3\) However, little was known about patients with suspected COVID-19. We investigated 133 suspected COVID-19 patients who were admitted to Wuhan Union Hospital from February 13, 2020 to February 16, 2020. Of the 133 patients, 35 patients had no laboratory evidence of COVID-19 infection even many SARS-CoV-2 nucleic acid and antibody tests were done. In this study, we aimed to compare the demographic, clinical, laboratory, and radiological characteristics of patients with...
confirmed COVID-19 and antibody negative (AbN) probable COVID-19. And we want to offer some suggestions to managing AbN probable COVID-19 patients since some of them may not be COVID-19 infection.

**Methods**

**Study design and participants**

This single-centre, retrospective study (clinical trial identifier ChiCTR2000029770) was conducted at Wuhan Union Hospital (including two designated branch hospitals to treat patients with COVID-19). The study was approved by the Institutional Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (20200036), the requirement for informed consent was exempted by the Ethics Committee.

The inclusion criteria were adult patients with confirmed and suspected COVID-19 on admission. Patients with negative RT-PCR testing results but didn’t test SARS-CoV-2 antibody were excluded.

From February 13 to February 16, 2020, 616 confirmed COVID-19 patients and 133 suspected COVID-19 patients were admitted in Wuhan Union Hospital. Of the 133 suspected patients, 98 didn’t test SARS-CoV-2 antibody, 35 showed negative serological SARS-CoV-2 antibody results (Figure 1).

**Diagnosis of COVID-19**

The diagnosis was made and clinical classification of COVID-19 was performed for the patients according to the Guidelines of the Diagnosis and Treatment of New Coronavirus Pneumonia (version 7) published by the National Health Commission of China. The diagnosis was established on the basis of (1) epidemiological history, (2) fever and/or other respiratory symptoms, (3) presence or
absence of the imaging findings of novel coronavirus pneumonia, and (4) normal/reduced white blood
cell count and normal/reduced lymphocyte count. A patient was taken as suspected case if she or he
had epidemiological history, two of the aforementioned clinical presentations, or had no clear
epidemiological history but had three of the clinical presentations. Suspected cases were considered to
be confirmed if (1) real-time fluorescence RT-PCR for SARS-CoV-2 nucleic acid yielded positive
results, or (2) Positive SARS-CoV-2 specific IgM and IgG antibody, or (3) Demonstration of a
four-fold or greater increase in IgG antibody titer or conversion from a negative to a positive result
between acute- and convalescent-phase serum specimens.

Data Collection

Medical records were also reviewed for detail demographic and clinical information. All discharged
patients with suspected COVID-19 infection were interviewed by telephone to collect the updated
SARS-CoV-2 nucleic acid and antibody results. AbN probable COVID-19 patients were further
investigated by telephone interview to record their potential contact and exposure history before and
after admitted to hospital.

Statistical Analysis

Categorical variables were presented as frequency rates and percentages, and continuous variables
were expressed as mean±standard deviation (SD) if they were normally distributed or median
(interquartile range [IQR]) if they were not. Proportions for categorical variables were compared
using the $\chi^2$ test or Fisher’s exact test. Means for continuous variables were compared using
independent group $t$ test when the data were normally distributed. Otherwise, the Wilcoxon rank-sum
test was employed. Missing data have been mentioned in the relevant tables, and there was no other
missing data, unless otherwise noted. All statistical analyses were performed by using SAS software package (version 9.4).

Results

Demographic and clinical features in patients with confirmed and AbN probable COVID-19

The demographic and clinical characteristics at admission for the 616 confirmed and the 35 AbN probable patients are listed in Table 1. The proportion of female subjects in the confirmed COVID-19 group was 57.5%, while in AbN probable COVID-19 group was 57.1%. The median age of AbN probable patients was 55 (IQR, 37.0-68.0) years, which was significantly younger than confirmed patients (64 [IQR, 53.0-70.0] years). The median duration from symptoms onset to admission in AbN probable patients was 8 (IQR, 5-14) days, while in confirmed patients was 13 (IQR, 7-20) days, 27 (77.1%) of the AbN probable patients were hospitalized within 14 days after symptoms onset. On admission, the most common presenting symptoms of the AbN suspected COVID-19 patients were fever (19 [54.3%]), cough (19 [54.3%]), and weakness (12 [34.3%]). 11 (31.4%) of the AbN probable COVID-19 patients had chronic diseases, including hypertension (9 [25.7%]), chronic cardiac disease (3 [8.6%]), diabetes (4 [11.4%]), and chronic renal disease (1 [2.9%]). No significant differences were seen in any symptoms or comorbidities between confirmed patients and AbN probable patients.

Laboratory and Radiological Findings in patients with confirmed and AbN probable COVID-19

Table 2 shows the laboratory findings and chest CT scan on admission. Compared with confirmed patients, AbN probable patients showed higher lymphocyte count (P=0.004), CD8 lymphocytes proportion (P=0.024) and albumin level (P<0.001). The lactate dehydrogenase (LDH, P=0.011),
erythrocyte sedimentation rate (ESR, P<0.001) and fibrinogen level (P=0.001) were much lower in AbN probable patients than confirmed COVID-19 patients. Of the 35 AbN probable patients, 34 showed abnormal chest CT scan, 32 of them showed patchy or ground-glass opacity. During the course of the disease, 5 (14.3%) patients always showed unilateral lung involvement while 29 (82.9%) patients showed bilateral involvement. No significant differences were seen in chest CT scan between confirmed patients and AbN probable patients.

**Epidemiology and pathogen detection in patients with AbN probable COVID-19**

All the AbN probable patients had tested at least 3 times of nucleic acid, the median times of SARS-CoV-2 nucleic acid test was 6.0 (IQR, 4.0-8.0). Among the 35 AbN probable COVID-19 patients, the duration from symptoms onset to first antibody test was 50.0 (IQR, 24.0-72.0) days, 12 patients had their antibody test two or more times, 8 patients tested the antibodies in two or more places in different time (Table 1). Figure 2 shows the time lines of SARS-CoV-2 nucleic acid and antibody test in the 12 patients who tested antibody two or more times. Another 23 AbN probable COVID-19 patients who tested antibody only once (Figure S1). During hospitalization, 20 of the AbN probable patients had tested serological mycoplasma and chlamydia antibodies, 15 of them showed positive mycoplasma or chlamydia IgG antibodies. Of the 35 AbN probable patients, a family cluster of 3 patients were admitted to the hospital and lived in one isolation ward. Table S1 shows the pathogens examined by the 3 patients. The 3 patients were eventually diagnosed as non- COVID-19 infection.

Of the 35 AbN probable COVID-19 patients, 14 had close contacted with confirmed or suspected COVID-19 patients before admission, 21 patients don’t know whether they had contacted patients
with COVID-19. All the 35 patients had contacted with confirmed patients in hospital (in fever outpatient clinics or isolation wards), 32 patients shared the same room with confirmed COVID-19 patients. During hospitalization, the 35 patients almost wore face mask all the time, even when sleeping. All the patients except the 3 index family members claimed that they had maintained a distance of more than one meter when contacting with other patients. Additional measures were also taken by hospital and health-care workers to prevent patients from hospital acquired infection: 1) All health-care workers should disinfect their hands before contact with another patient; 2) Maintaining ventilation; 3) Surface disinfection of isolation wards every day; 4) Air disinfection for at least 1 hour per day. After discharged from hospital, all of them had negative SARS-CoV-2 nucleic acid tests and no one developed symptoms again.

**Discussion**

Our study compares the clinical features between patients with confirmed COVID-19 and those with AbN probable COVID-19. We found that, compared with features in patients with confirmed COVID-19, patients with AbN probable COVID-19 were younger, showed higher lymphocyte count, albumin level and had lower LDH and ESR level. Previous studies have shown older age, lower lymphocyte count and higher levels of LDH to be associated with severe COVID-19 at admission.\cite{9,10} Another study demonstrated that decreased albumin was independent risk factor which influence the improvement of COVID-19 patients.\cite{11} Therefore, the conditions of patients with AbN probable COVID-19 were less critical than those patients with confirmed COVID-19. However, no significant differences were seen in any symptoms and chest CT findings between confirmed and AbN probable patients, suggesting that it’s hard for physicians to distinguish confirmed and AbN probable COVID-19 patients on admission.
Several reasons might contribute to the negative antibody test in the 35 patients: 1) false negative results of antibody test; 2) the delay of SARS-CoV-2 antibody production; 3) some of the them were conventional infection rather than COVID-19 infection. A study in our hospital showed the sensitivity of IgM and IgG test in suspected COVID-19 patients were 87.5% and 70.8%, respectively. A study in Italy even showed that IgG had 100% sensitivity on day 12 from symptoms onset. Two independent studies also demonstrated that on day 19 and day 15, the SARS-CoV-2 antibody could be tested on all the confirmed COVID-19 patients. In our study, a family cluster of 3 patients were diagnosed as non-COVID-19 infection. Of the other 32 AbN probable patients, 23 tested the SARS-CoV-2 antibody once, 9 patients had their antibody test two or more times, 8 patients even tested the SARS-CoV-2 antibodies in two or more places in different time. All of them had their antibody test after 15 days of symptoms onset. Therefore, based on the reported sensitivity and specificity of SARS-CoV-2 antibody tests, it is very likely that most of the AbN probable patients were not infected with COVID-19.

During the pandemic of COVID-19, early diagnosis and isolation of infections are essential for preventing further spread of COVID-19. WHO suggested to screen and isolate all patients with suspected COVID-19 at the first point of contact with the health care system. However, isolate all suspected patients might put some patients in danger, since some of them might not be infected with SARS-CoV-2. While conducting telephone interviews, we found those AbN probable or suspected patients have been suffering much anxiety and depress so far. A study of Vietnam showed suspected COVID-19 patients had a lower health-related quality of life and had a lower health-related quality of life. Under this circumstance, measures should be taken to protect suspected patients from hospital acquired COVID-19 infection. Of the 35 AbN probable cases, 32 had
contacted and shared one room with confirmed COVID-19 patients. However, none of them showed any symptoms or positive SARS-CoV-2 nucleic acid results after discharged from hospital. These results demonstrated that none of the 35 AbN probable patients got hospital acquired COVID-19 infection. Since it is impossible for us to find exposure control for those patients, we can’t draw any conclusions about how to protect such patients. However, the following measures taken by hospital, patients and health-care workers might protect them from hospital acquired COVID-19 infection: 1) Daily disinfection isolation ward; 2) Maintaining ventilation in isolation wards; 3) Patients should wear surgical mask and keep at least 1 meter away from each other; 4) Health-care workers should disinfection their hands before touching patients. If possible, we also suggest to quarantine the confirmed and suspected COVID-19 patients separately.

Our study had several limitations. First, this is a retrospective study and there is no definite evidence that the AbN probable patients were infected with other pathogens. Second, not all suspected COVID-19 patients had tested SARS-CoV-2 antibody, those patients were excluded from our study and may cause selection bias. Third, no exposure control could be founded for the 35 AbN probable COVID-19 patients, we could not determine which measure are useful to protect patients from hospital acquired COVID-19 infection.

Conclusions

Our study demonstrated that the conditions of patients with AbN probable COVID-19 were less critical than those of patients with confirmed COVID-19. But in fact, we cannot distinguish without SARS-CoV-2 infection from suspected COVID in clinical practice. We firstly points out the realistic dilemma about managing patients with suspected COVID-19: some patients without SARS-CoV-2
infection may be considered as suspected COVID-19 cases and share one isolation ward with confirmed COVID-19 patients in hospital. Wearing face mask, maintaining social distance, room ventilation and disinfection might be useful to protect patients from hospital acquired SARS-CoV-2 infection in the pandemic.

**Funding** This work was supported by the State Project for Essential Drug Research and Development, China (no. 2019ZX09301001) and the National Natural Science Foundation of China (no. 81770096 and no. 81700091). The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

**Contributors**

YJ and FW designed the study, LD, MG, EZ, JF, XW and LW collected the epidemiological and clinical data. LD, MG, and EZ summarized all data. SZ, LD and MG analyzed and drafted the manuscript. All authors revised the final manuscript.

**Declaration of interests**

We declare no competing interests.

**References**


### Table 1 Demographic and Baseline Characteristics of patients with confirmed and AbN probable COVID-19

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Confirmed cases (n=616)</th>
<th>AbN probable cases (n=35)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>n (%) 354 (57.5%)</td>
<td>20 (57.1%)</td>
<td>0.970‡</td>
</tr>
<tr>
<td>Male</td>
<td>n (%) 262 (42.5%)</td>
<td>15 (42.9%)</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>Median (IQR) 64 (53-70)</td>
<td>55 (37-68)</td>
<td>0.017*</td>
</tr>
<tr>
<td>≤50</td>
<td>n (%) 130 (21.10%)</td>
<td>16 (45.71%)</td>
<td></td>
</tr>
<tr>
<td>51-60</td>
<td>n (%) 105 (17.05%)</td>
<td>2 (5.71%)</td>
<td></td>
</tr>
<tr>
<td>61-70</td>
<td>n (%) 245 (39.77%)</td>
<td>12 (34.29%)</td>
<td></td>
</tr>
<tr>
<td>&gt;70</td>
<td>n (%) 136 (22.08%)</td>
<td>5 (14.29%)</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>n (%) 23 (3.80%)</td>
<td>2 (5.70%)</td>
<td>0.640§</td>
</tr>
<tr>
<td>Symptoms onset to admission, days</td>
<td>Median (IQR) 13 (7.00-20.00)</td>
<td>8 (5-14)</td>
<td>0.006*</td>
</tr>
<tr>
<td>Fever</td>
<td>n (%) 425 (69.0%)</td>
<td>19 (54.3%)</td>
<td>0.069‡</td>
</tr>
<tr>
<td>Cough</td>
<td>n (%) 375 (60.9%)</td>
<td>19 (54.3%)</td>
<td>0.438‡</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>n (%) 70 (11.4%)</td>
<td>3 (8.6%)</td>
<td>0.787§</td>
</tr>
</tbody>
</table>
Weakness n (%) 211 (34.3%) 12 (34.3%) 0.997‡
Diarrhea n (%) 82 (13.3%) 2 (5.7%) 0.297§
Myalgia n (%) 111 (18.0%) 2 (5.7%) 0.067§
Sore throat n (%) 68 (11.0%) 4 (11.4%) >0.999§
Shortness of breath n (%) 214 (34.7%) 12 (34.3%) 0.956‡

Comorbidities
Any n (%) 276 (44.8%) 11 (31.4%) 0.121‡
Hypertension n (%) 188 (30.5%) 9 (25.7%) 0.547‡
Chronic cardiac disease n (%) 56 (9.1%) 3 (8.6%) >0.999§
Cerebrovascular disease n (%) 9 (1.5%) 1 (2.9%) 0.427§
Chronic respiratory disease n (%) 14 (2.3%) 0 >0.999§
Chronic renal disease n (%) 7 (1.1%) 1 (2.9%) 0.359§
Diabetes n (%) 78 (12.7%) 4 (11.4%) >0.999§
Chronic liver disease n (%) 9 (1.5%) 1 (2.9%) 0.427§

Vital signs on admission
Body temperature on admission, °C
Mean (SD) 36.6 (0.60) 36.5 (0.27) 0.202†
Respiratory rate, breaths per min
Mean (SD) 20 (2.29) 20 (2.12) 0.407†
Heart rate, beat per minute
Mean (SD) 83 (12.07) 82 (13.34) 0.722†
Systolic blood pressure
Mean (SD) 128 (17.01) 129 (16.05) 0.982†
Diastolic blood pressure
Mean (SD) 78 (11.22) 82 (13.75) 0.061†

Continuous variables were compared using Wilcoxon rank-sum test.
*Calculated using the Wilcoxon rank-sum test.
†Calculated using the unpaired t test.
‡Calculated using the χ² test.
§Calculated using the Fisher’s exact test.

Table 2 Laboratory and Radiological Findings of patients with confirmed and AbN probable COVID-19

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Confirmed cases (n=616)</th>
<th>AbN probable cases (n=35)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory Findings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leucocytes count, × 10⁹/L</td>
<td>5.66 (2.16)</td>
<td>5.55 (1.64)</td>
<td>0.756‡</td>
</tr>
<tr>
<td>Neutrophils count, × 10⁹/L</td>
<td>3.80 (2.79)</td>
<td>3.44 (1.36)</td>
<td>0.454‡</td>
</tr>
<tr>
<td>Lymphocyte count, × 10⁹/L</td>
<td>1.32 (0.70)</td>
<td>1.68 (0.62)</td>
<td>0.064†</td>
</tr>
<tr>
<td>Hematocrit, %</td>
<td>36.20 (33.50-39.50)</td>
<td>38.80 (33.58-42.03)</td>
<td>0.049*</td>
</tr>
<tr>
<td>Hemoglobin, g/L</td>
<td>122.21 (16.12)</td>
<td>128.09 (16.94)</td>
<td>0.040†</td>
</tr>
<tr>
<td>Platelets count, × 10⁹/L</td>
<td>225.00 (172.00-293.25)</td>
<td>212.50 (174.50-242.25)</td>
<td>0.065*</td>
</tr>
<tr>
<td>Total bilirubin, μmol/L</td>
<td>13.80 (7.58)</td>
<td>14.99 (5.81)</td>
<td>0.366†</td>
</tr>
<tr>
<td>Direct bilirubin, μmol/L</td>
<td>4.31 (4.07)</td>
<td>4.40 (2.35)</td>
<td>0.907†</td>
</tr>
<tr>
<td>Albumin, g/L</td>
<td>36.94 (4.86)</td>
<td>41.44 (4.47)</td>
<td>&lt;0.001†</td>
</tr>
<tr>
<td>Globin, g/L</td>
<td>26.90 (24.50-30.00)</td>
<td>23.70 (21.63-30.73)</td>
<td>0.016*</td>
</tr>
<tr>
<td>ALT, U/L</td>
<td>34.61 (35.85)</td>
<td>27.12 (19.45)</td>
<td>0.228†</td>
</tr>
<tr>
<td>Test</td>
<td>Reference Range</td>
<td>Test Value</td>
<td>p-value</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>31.32 (22.76) - 30.26 (25.46)</td>
<td>0.794†</td>
<td></td>
</tr>
<tr>
<td>Urea nitrogen, mmol/L</td>
<td>4.29 (2.30) - 4.31 (1.26)</td>
<td>0.960†</td>
<td></td>
</tr>
<tr>
<td>Creatinine, μmol/L</td>
<td>74.35 (22.46) - 77.34 (16.49)</td>
<td>0.445†</td>
<td></td>
</tr>
<tr>
<td>GGT, U/L</td>
<td>36.91 (40.88) - 33.24 (56.86)</td>
<td>0.619†</td>
<td></td>
</tr>
<tr>
<td>Creatine kinase, U/L</td>
<td>63.00 (45.50-97.00) - 80.00 (62.50-156.00)</td>
<td>0.002*</td>
<td></td>
</tr>
<tr>
<td>LDH, U/L</td>
<td>221.58 (84.35) - 183.24 (85.82)</td>
<td>0.011†</td>
<td></td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>20.72 (33.19) - 13.51 (29.34)</td>
<td>0.237†</td>
<td></td>
</tr>
<tr>
<td>BNP, pg/ml</td>
<td>61.38 (264.32) - 62.98 (127.50)</td>
<td>0.977†</td>
<td></td>
</tr>
<tr>
<td>hs-TnT, ng/L</td>
<td>2.70 (1.50-6.15) - 2.30 (1.10-3.65)</td>
<td>0.135*</td>
<td></td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>37.00 (20.00-61.00) - 13.00 (6.25-27.50)</td>
<td>&lt;0.001*</td>
<td></td>
</tr>
<tr>
<td>Procalcitonin, ng/ml</td>
<td>0.06 (0.04-0.15) - 0.04 (0.04-0.08)</td>
<td>0.120*</td>
<td></td>
</tr>
<tr>
<td>D-dimer, mg/L</td>
<td>1.69 (6.46) - 0.77 (1.69)</td>
<td>0.443†</td>
<td></td>
</tr>
<tr>
<td>PT, s</td>
<td>13.49 (1.44) - 13.18 (1.09)</td>
<td>0.230†</td>
<td></td>
</tr>
<tr>
<td>APTT, s</td>
<td>36.50 (33.70-39.80) - 35.70 (33.05-39.40)</td>
<td>0.358*</td>
<td></td>
</tr>
<tr>
<td>INR</td>
<td>1.05 (0.16) - 1.02 (0.11)</td>
<td>0.248†</td>
<td></td>
</tr>
<tr>
<td>Fibrinogen, g/L</td>
<td>4.43 (1.97) - 3.26 (1.19)</td>
<td>0.001†</td>
<td></td>
</tr>
<tr>
<td>CD3+T cell, %</td>
<td>73.91 (11.24) - 75.38 (10.69)</td>
<td>0.471†</td>
<td></td>
</tr>
<tr>
<td>CD4+T cell, %</td>
<td>47.08 (40.89-53.82) - 44.06 (39.56-47.99)</td>
<td>0.063*</td>
<td></td>
</tr>
<tr>
<td>CD8+T cell, %</td>
<td>23.62 (8.77) - 27.22 (8.41)</td>
<td>0.024†</td>
<td></td>
</tr>
<tr>
<td>IL-2, pg/ml</td>
<td>2.84 (0.83) - 2.80 (0.64)</td>
<td>0.780†</td>
<td></td>
</tr>
<tr>
<td>IL-4, pg/ml</td>
<td>2.40 (1.06) - 2.41 (0.97)</td>
<td>0.981†</td>
<td></td>
</tr>
<tr>
<td>IL-6, pg/ml</td>
<td>37.76 (80.54) - 42.50 (66.59)</td>
<td>0.748†</td>
<td></td>
</tr>
<tr>
<td>IL-10, pg/ml</td>
<td>4.36 (10.86) - 3.38 (1.32)</td>
<td>0.617†</td>
<td></td>
</tr>
<tr>
<td>TNF-a, pg/ml</td>
<td>3.10 (2.22-4.86) - 2.89 (2.01-4.19)</td>
<td>0.537*</td>
<td></td>
</tr>
<tr>
<td>IFN-γ, pg/ml</td>
<td>2.56 (2.59) - 2.46 (1.41)</td>
<td>0.833†</td>
<td></td>
</tr>
</tbody>
</table>

**Radiological Findings**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Reference Range</th>
<th>Test Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unilateral</td>
<td>64 (10.40%) - 5 (14.70%)</td>
<td>0.426‡</td>
</tr>
<tr>
<td>Bilateral</td>
<td>552 (89.60%) - 29 (85.30%)</td>
<td>0.659§</td>
</tr>
<tr>
<td>Patchy and ground-glass opacity</td>
<td>589 (95.60%) - 32 (94.10%)</td>
<td>0.659§</td>
</tr>
</tbody>
</table>

Continuous variables were expressed as mean (SD) if they were normally distributed or median (IQR) if they were not. Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; GGT, Gamma-Glutamyl Transferase; LDH, Lactate dehydrogenase; BNP, type B natriuretic peptide; hs-TnT1, High sensitive Troponin I; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; PT, Prothrombin time; APTT, Activated partial thromboplastin time; INR, International normalized ratio; IL-2, Interleukin-2; IL-4, Interleukin-4; IL-6, Interleukin-6; IL-10, Interleukin-10; TNF-a, Tumor necrosis factor-a; IFN-γ, interferon-γ.

*Calculated using the Wilcoxon rank-sum test.
†Calculated using the unpaired t test.
‡Calculated using the χ² test.
§Calculated using the Fisher’s exact test.
Table 3 SARS-CoV-2 nucleic acid and antibody detection in patients with AbN probable COVID-19

<table>
<thead>
<tr>
<th>Patients with AbN probable COVID-19 (n=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Times of nucleic acid test, days</td>
</tr>
<tr>
<td>Times of nucleic acid test before or during admission, days</td>
</tr>
<tr>
<td>Times of nucleic acid test after discharged from hospital, days</td>
</tr>
<tr>
<td>Antibody detection times, days</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>&gt;2</td>
</tr>
<tr>
<td>Symptoms onset to first antibody test, days</td>
</tr>
<tr>
<td>&lt;15</td>
</tr>
<tr>
<td>15-30</td>
</tr>
<tr>
<td>&gt;30</td>
</tr>
</tbody>
</table>

Figure 1. Study flow.

Figure 2. Timeline of nucleic acid and antibody detection of the 12 AbN probable COVID-19 patients who had tested SARS-CoV-2 more than once. Day 0 refers to the date of symptoms onset.
Patients with Confirmed and suspected COVID-19 admitted to Wuhan Union Hospital from February 13 to February 16, 2020 (n=749)

Patients with confirmed COVID-19 (n=616)

Patients with suspected COVID-19 (n=133)

Patients didn’t test SARS-CoV-2 antibody (n=62)

Patients didn’t test SARS-CoV-2 antibody during hospitalization and can not be reached after discharged from hospital (n=36)

Patients without antibody against SARS-CoV-2 (n=35)

Patient 1
Day 3  Day 7
Day 10  Day 14
Day 17  Day 21
Day 24  Day 28
Day 31  Day 35
Day 38  Day 42
Day 45  Day 49
Day 52

Patient 2
Day 3  Day 7  Day 14
Day 21  Day 28  Day 35
Day 42  Day 49  Day 56

Patient 3
Day 3  Day 7  Day 10  Day 14  Day 17  Day 21
Day 24  Day 28  Day 31  Day 35  Day 38  Day 42
Day 45  Day 49  Day 53  Day 57

Patient 4
Day 3
Day 7  Day 11  Day 15
Day 19  Day 23  Day 27
Day 31  Day 35  Day 39
Day 43  Day 47  Day 51  Day 55

Patient 5
Day 3  Day 7  Day 11  Day 15
Day 19  Day 23  Day 27  Day 31  Day 35
Day 39  Day 43  Day 47  Day 51  Day 55

Patient 6
Day 3  Day 7  Day 10  Day 14
Day 17  Day 21  Day 25  Day 29  Day 33  Day 37  Day 41  Day 45  Day 49

Patient 7
Day 3  Day 7  Day 10  Day 14
Day 17  Day 21  Day 25  Day 29  Day 33  Day 37  Day 41  Day 45  Day 49

Patient 8
Day 3  Day 7  Day 10  Day 14
Day 17  Day 21  Day 25  Day 29  Day 33  Day 37  Day 41  Day 45  Day 49

Patient 9
Day 3  Day 7  Day 10  Day 14
Day 17  Day 21  Day 25  Day 29  Day 33  Day 37  Day 41  Day 45  Day 49

Patient 10
Day 3  Day 7  Day 10  Day 14
Day 17  Day 21  Day 25  Day 29  Day 33  Day 37  Day 41  Day 45  Day 49

Patient 11
Day 3  Day 7  Day 10  Day 14
Day 17  Day 21  Day 25  Day 29  Day 33  Day 37  Day 41  Day 45  Day 49

Patient 12
Day 3  Day 7  Day 10  Day 14
Day 17  Day 21  Day 25  Day 29  Day 33  Day 37  Day 41  Day 45  Day 49

Nucleic acid detection
Antibody detection